US Stock Market Move | The phase three trials of the epilepsy drug have achieved positive results. Xenon Pharmaceuticals Inc. (XENE.US) surged more than 42% at the opening.

On Monday, Xenon Pharmaceuticals Inc. (XENE.US) opened with a surge of over 42%, reaching $59.59. On the news front, on March 9th, the company announced that the phase 3 X-TOLE2 study of Azetukalner for the treatment of focal epilepsy met its primary endpoint, with a 53.2% reduction in median seizure frequency in the 25mg dose group compared to 10.4% in the placebo group, with a p-value of 0.000000000006. The company confirmed that the safety profile of Azetukalner was consistent with previous studies, showing good tolerability, and announced plans to submit a new drug application to the U.S. FDA for Azetukalner in the third quarter of 2026. Additionally, William Blair analyst Myles Minter maintained a Buy rating on Xenon Pharmaceuticals Inc.